| Income Statement | 2024-09-30 | |||
|---|---|---|---|---|
| Net revenue | 10,850 | |||
| Cost of revenue | 6,468 | |||
| Gross profit | 4,382 | |||
| Research and development expense, total | 917 | |||
| General and administrative expense, total | 1,283 | |||
| Selling and marketing expense, total | 2,877 | |||
| Operating expenses | 5,077 | |||
| Operating income (loss) | -695 | |||
| Gain (loss) on foreign currency transactions | -69 | |||
| Other income (loss), net | -47 | |||
| Interest expense, net | -605 | |||
| Nonoperating income (expense) | -721 | |||
| Income (loss) from continuing operations before income taxes, noncontrolling interest | -1,416 | |||
| Income tax (benefit) | 12 | |||
| Net loss | -1,428 | |||
| Foreign currency translation adjustments | 129 | |||
| Comprehensive income (loss), net of tax, attributable to parent | -1,299 | |||
| Basic eps | -0.04 | |||
| Diluted eps | -0.04 | |||
| Basic average shares | 36,083,000 | |||
| Diluted average shares | 36,083,000 | |||
BIOLASE, INC (BIOLQ)
BIOLASE, INC (BIOLQ)